159 related articles for article (PubMed ID: 8889038)
1. Gastrointestinal physiology-regulated dogs for bioavailability evaluation of an oral controlled-release dosage form composed of pulsatile release granules.
Sagara K; Yamada I; Matsuura Y; Kawata M; Shibata M
Biol Pharm Bull; 1996 Sep; 19(9):1184-8. PubMed ID: 8889038
[TBL] [Abstract][Full Text] [Related]
2. Enhanced transdermal absorption and pharmacokinetic evaluation of pranoprofen-ethylene-vinyl acetate matrix containing penetration enhancer in rats.
Cho CW; Choi JS; Yang KH; Shin SC
Arch Pharm Res; 2009 May; 32(5):747-53. PubMed ID: 19471890
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability study of commercial sustained-release preparations of diclofenac sodium in gastrointestinal physiology regulated-dogs.
Sagara K; Nagamatsu Y; Yamada I; Kawata M; Mizuta H; Ogawa K
Chem Pharm Bull (Tokyo); 1992 Dec; 40(12):3303-6. PubMed ID: 1294333
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal physiology-regulated dogs: utilization of a bioavailability study of a new thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine, an antagonist of platelet-activating factor, and its preparations.
Sagara K; Yamada I; Kawazoe Y; Mizuta H; Shibata M
Biol Pharm Bull; 1994 Jan; 17(1):117-20. PubMed ID: 8148798
[TBL] [Abstract][Full Text] [Related]
5. Utility of gastrointestinal physiology regulated-dogs: bioavailability study of a commercial sustained-release dosage form of theophylline.
Sagara K; Kawata M; Mizuta H; Shibata M
Biol Pharm Bull; 1994 Jul; 17(7):931-4. PubMed ID: 8000380
[TBL] [Abstract][Full Text] [Related]
6. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs.
Löbenberg R; Kim JS; Amidon GL
Eur J Pharm Biopharm; 2005 May; 60(1):17-23. PubMed ID: 15848051
[TBL] [Abstract][Full Text] [Related]
8. Enantiospecific disposition of pranoprofen in beagle dogs and rats.
Imai T; Nomura T; Aso M; Otagiri M
Chirality; 2003 May; 15(4):312-7. PubMed ID: 12666237
[TBL] [Abstract][Full Text] [Related]
9. In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit FS 30 D-coated pellets.
Gao C; Huang J; Jiao Y; Shan L; Liu Y; Li Y; Mei X
Int J Pharm; 2006 Sep; 322(1-2):104-12. PubMed ID: 16806752
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of pranoprofen in the elderly.
Kajiyama H; Fujimura A; Ebihara A; Hino Y
Int J Clin Pharmacol Res; 1991; 11(3):123-7. PubMed ID: 1809698
[TBL] [Abstract][Full Text] [Related]
11. The influence of fever on the pharmacokinetics of pranoprofen in elderly subjects.
Fujimura A; Kajiyama H; Ebihara A
J Clin Pharmacol; 1989 Jun; 29(6):500-3. PubMed ID: 2787808
[TBL] [Abstract][Full Text] [Related]
12. A Biopredictive In Vitro Comparison of Oral Locally Acting Mesalazine Formulations by a Novel Dissolution Model for Assessing Intraluminal Drug Release in Individual Subjects.
Karkossa F; Klein S
J Pharm Sci; 2018 Jun; 107(6):1680-1689. PubMed ID: 29499277
[TBL] [Abstract][Full Text] [Related]
13. Effect of gastric acidity on bioavailability of N,N-dimethylcarbamoylmethylalpha, 2-dimethyl-5H-[1]benzopyrano[2,3-b]pyridine-7-acetate, a new prodrug-type anti-inflammatory agent.
Yamada I; Goda T; Kawata M; Mizuta H; Ogawa K; Yokobe T
Chem Pharm Bull (Tokyo); 1989 Dec; 37(12):3372-5. PubMed ID: 2632086
[TBL] [Abstract][Full Text] [Related]
14. Sustained delivery of intact drug to the colon: mesalamine formulation and temporal gastrointestinal transit analysis.
Chuong MC; Christensen JM; Ayres JW
Pharm Dev Technol; 2009; 14(1):116-25. PubMed ID: 18821272
[TBL] [Abstract][Full Text] [Related]
15. Enhanced transdermal delivery of pranoprofen from the bioadhesive gels.
Shin SC; Cho CW
Arch Pharm Res; 2006 Oct; 29(10):928-33. PubMed ID: 17121190
[TBL] [Abstract][Full Text] [Related]
16. Prediction of in vivo drug release behavior of controlled-release multiple-unit dosage forms in dogs using a flow-through type dissolution test method.
Ikegami K; Tagawa K; Kobayashi M; Osawa T
Int J Pharm; 2003 Jun; 258(1-2):31-43. PubMed ID: 12753751
[TBL] [Abstract][Full Text] [Related]
17. Stereoselective disposition of pranoprofen, a nonsteroidal antiinflammatory drug, in rabbits.
Nomura T; Imai T; Otagiri M
Biol Pharm Bull; 1993 Mar; 16(3):298-303. PubMed ID: 8364476
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective Pharmacokinetics of Ketoprofen After Oral Administration of Modified-Release Formulations in Caucasian Healthy Subjects.
Lorier M; Magallanes L; Ibarra M; Guevara N; Vázquez M; Fagiolino P
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):787-793. PubMed ID: 26590950
[TBL] [Abstract][Full Text] [Related]
19. Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration.
Abrego G; Alvarado H; Souto EB; Guevara B; Bellowa LH; Parra A; Calpena A; Garcia ML
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):261-70. PubMed ID: 25681744
[TBL] [Abstract][Full Text] [Related]
20. Eudraginated polymer blends: a potential oral controlled drug delivery system for theophylline.
Emeje M; John-Africa L; Isimi Y; Kunle O; Ofoefule S
Acta Pharm; 2012 Mar; 62(1):71-82. PubMed ID: 22472450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
